Search

Your search keyword '"Sönnerborg, Anders"' showing total 27 results
Start Over Author "Sönnerborg, Anders" Publisher wiley
27 results on '"Sönnerborg, Anders"'

3. Pre‐existing singleton E138A mutations in the reverse transcriptase gene do not affect the efficacy of first‐line antiretroviral therapy regimens using rilpivirine in human immunodeficiency virus‐infected patients

Author

Kuznetsova, Anna, primary, Lebedev, Aleksey, additional, Gromov, Konstantin, additional, Kazennova, Elena, additional, Zazzi, Maurizio, additional, Incardona, Francesca, additional, Sönnerborg, Anders, additional, and Bobkova, Marina, additional

Published
2022
Full Text
View/download PDF

4. HIV incidence in the Estonian population in 2013 determined using the HIV-1 limiting antigen avidity assay

Author

Soodla, P., Simmons, R., Huik, K., Pauskar, M., Jõgeda, E. -L., Rajasaar, H., Kallaste, E., Maimets, M., Avi, R., Murphy, G., Porter, K., Lutsar, I., Del Amo, Julia, Meyer, Laurence, Bucher, Heiner C., Chêne, Geneviève, Hamouda, Osamah, Pillay, Deenan, Prins, Maria, Rosinska, Magda, Sabin, Caroline, Touloumi, Giota, Olson, Ashley, Cartier, Andrea, Fradette, Lorraine, Walker, Sarah, Babiker, Abdel, De Luca, Andrea, Fisher, Martin, Muga, Roberto, Kelleher, Tony, Cooper, David, Grey, Pat, Finlayson, Robert, Bloch, Mark, Ramacciotti, Tim, Gelgor, Linda, Smith, Don, Zangerle, Robert, Gill, John, Dabis, Francois, Thiebaut, Rodolphe, Costagliola, Dominique, Guiguet, Marguerite, Vanhems, Philippe, Chaix, Marie-Laure, Ghosn, Jade, Boufassa, Faroudy, Meixenberger, Karolin, Bannert, Norbert, Bartmeyer, Barbara, Antoniadou, Anastasia, Chrysos, Georgios, Daikos, Georgios L., Pantazis, Nikos, Katsarou, Olga, Rezza, Giovanni, Dorrucci, Maria, Monforte, Antonella d'Arminio, Geskus, Ronald, van der Helm, Jannie, Schuitemaker, Hanneke, Sannes, Mette, Brubakk, Oddbjorn, Kran, Anne-Marte Bakken, Rosinska, Magdalena, Tor, Jordi, de Olalla, Patricia Garcia, Cayla, Joan, Moreno, Santiago, Monge, Susana, del Romero, Jorge, Pérez-Hoyos, Santiago, Sönnerborg, Anders, Günthard, Huldrych, Scherrer, Alexandra, Malyuta, Ruslan, Johnson, Anne, Phillips, Andrew, Morrison, Charles, Price, Matt A., Giaquinto, Carlo, Grarup, Jesper, Kirk, Ole, Bailey, Heather, Volny Anne, Alain, Panteleev, Alex, Thorne, Claire, Aboulker, Jean-Pierre, Albert, Jan, Asandi, Silvia, De Wit, Stéphane, Reiss, Peter, Gatell, José, Karpov, Igor, Ledergerber, Bruno, Møller, Claus, Rakhmanova, Aza, Rockstroh, Jürgen, Sandhu, Manjinder, Dedes, Nikos, Pizzuti, David, Faggion, Silvia, Raben, Dorthe, Schwimmer, Christine, Scott, Martin, APH - Global Health, Infectious diseases, Epidemiology and Data Science, Experimental Immunology, APH - Aging & Later Life, and Global Health

Subjects
Male, 0301 basic medicine, HIV Infections, Immunoenzyme Techniques, 0302 clinical medicine, Epidemiology, Pharmacology (medical), Prospective Studies, 030212 general & internal medicine, media_common, Aged, 80 and over, education.field_of_study, Transmission (medicine), Incidence, Health Policy, Incidence (epidemiology), virus diseases, Middle Aged, 3. Good health, Infectious Diseases, Female, epidemiology, Viral load, Adult, Estonia, medicine.medical_specialty, Adolescent, 030106 microbiology, Population, Eastern Europe, recent infection testing algorithm, Young Adult, recent HIV infection, 03 medical and health sciences, Internal medicine, medicine, Humans, HIV serological assay, media_common.cataloged_instance, European union, Seroconversion, education, Aged, injecting drug users, Diagnostic Tests, Routine, business.industry, Public health, HIV, Immunology, HIV-1, business
Abstract

OBJECTIVES: Estonia has one the highest number of new HIV diagnoses in the European Union, mainly among injecting drug users and heterosexuals. Little is known of HIV incidence, which is crucial for limiting the epidemic. Using a recent HIV infection testing algorithm (RITA) assay, we aimed to estimate HIV incidence in 2013. METHODS: All individuals aged ≥18 years newly-diagnosed with HIV in Estonia January- December 2013, except blood donors and those undergoing antenatal screening, were included. Demographic and clinical data were obtained from the Estonian Health Board and the Estonian HIV-positive patient database. Serum samples were tested for recent infection using the LAg-avidity EIA assay. HIV incidence was estimated based on previously published methods. RESULTS: Of 69,115 tested subjects, 286 (0.41%) were newly-diagnosed with HIV with median age of 33 years (IQR: 28–42) and 65% male. Self-reported routes of HIV transmission were mostly heterosexual contact (n = 157, 53%) and injecting drug use (n = 62, 21%); 64 (22%) were with unknown risk group. Eighty two (36%) were assigned recent, resulting in estimated HIV incidence of 0.06%, corresponding to 642 new infections in 2013 among the non-screened population. Incidence was highest (1.48%) among people who inject drugs. CONCLUSIONS: These high HIV incidence estimates in Estonia call for urgent action of renewed targeted public health promotion and HIV testing campaigns.

Published
2017

13. Selection of drug‐resistant HIV‐1 during the early phase of viral decay is uncommon in treatment‐naïve patients initiated on a three‐ or four‐drug antiretroviral regimen including lamivudine

Author

Bergroth, Tobias, primary, Ekici, Halime, additional, Gisslén, Magnus, additional, Loes, Sabine Kinloch‐de, additional, Goh, Li‐Ean, additional, Freedman, Andrew, additional, Lampe, Fiona, additional, Johnson, Margaret A., additional, and Sönnerborg, Anders, additional

Published
2008
Full Text
View/download PDF

15. Inter‐laboratory comparison of HCV‐RNA assay results: Implications for multi‐centre research

Author

Pembrey, Lucy, primary, Newell, Marie‐Louise, additional, Tovo, Pier‐Angelo, additional, van Drimmelen, Harry, additional, Quinti, Isabella, additional, Furlini, Giuliano, additional, Galli, Silvia, additional, Meliconi, Maria Grazia, additional, Burns, Sheila, additional, Hallam, Nick, additional, Sönnerborg, Anders, additional, Cilla, Gustavo, additional, Serrano, Esther, additional, Laccetti, Paolo, additional, Portella, Giuseppe, additional, Polywka, Susanne, additional, Icardi, Giancarlo, additional, Bruzzone, Bianca, additional, Balbo, Luciano, additional, and Alfarano, Alda, additional

Published
2002
Full Text
View/download PDF

24. Isolation of human immunodeficiency virus (HIV) from plasma during primary HIV infection

Author

Albert, Jan, primary, Gaines, Hans, additional, Sönnerborg, Anders, additional, Nyström, Gunnel, additional, Pehrson, Pehr Olov, additional, Chiodi, Francesca, additional, von Sydow, Madeleine, additional, Moberg, Lars, additional, Lidman, Knut, additional, Christensson, Bertil, additional, Åsjö, Birgitta, additional, and Fenyö, Eva Maria, additional

Published
1987
Full Text
View/download PDF

26. Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe.

Author

Rossetti B, Fabbiani M, Di Carlo D, Incardona F, Abecasis A, Gomes P, Geretti AM, Seguin-Devaux C, Garcia F, Kaiser R, Modica S, Shallvari A, Sönnerborg A, and Zazzi M

Subjects
Drug Resistance, Viral, Europe, Heterocyclic Compounds, 3-Ring therapeutic use, Humans, Integrases therapeutic use, Oxazines therapeutic use, Viral Load, HIV Infections drug therapy, HIV Integrase genetics, HIV Integrase Inhibitors pharmacology, HIV Integrase Inhibitors therapeutic use
Abstract

Objectives: To explore the effectiveness and durability of integrase strand transfer inhibitor (INSTI)-based regimens in pre-treated subjects., Methods: Treatment-experienced individuals starting an INSTI-based regimen during 2012-2019 were selected from the INTEGRATE collaborative study. The time to virological failure [VF: one measurement of viral load (VL) ≥ 1000 copies/mL or two ≥ 50 copies/ml or one VL measurement ≥ 50 copies/mL followed by treatment change] and to INSTI discontinuation were evaluated., Results: Of 13 560 treatments analysed, 4284 were from INSTI-naïve, non-viraemic (IN-NV) individuals, 1465 were from INSTI-naïve, viraemic (IN-V) individuals, 6016 were from INSTI-experienced, non-viraemic (IE-NV) individuals and 1795 were from INSTI-experienced, viraemic (IE-V) individuals. Major INSTI drug resistance mutations (DRMs) were previously detected in 4/519 (0.8%) IN-NV, 3/394 (0.8%) IN-V, 7/1510 (0.5%) IE-NV and 25/935 (2.7%) IE-V individuals. The 1-year estimated probabilities of VF were 3.1% [95% confidence interval (CI): 2.5-3.8] in IN-NV, 18.4% (95% CI: 15.8-21.2) in IN-V, 4.2% (95% CI: 3.6-4.9) in IE-NV and 23.9% (95% CI: 20.9-26.9) in IE-V subjects. The 1-year estimated probabilities of INSTI discontinuation were 12.1% (95% CI: 11.1-13.0) in IN-NV, 19.6% (95% CI: 17.5-21.6) in IN-V, 10.8% (95% CI: 10.0-11.6) in IE-NV and 21.7% (95% CI: 19.7-23.5) in IE-V subjects., Conclusions: Both VF and INSTI discontinuation occur at substantial rates in viraemic subjects. Detection of DRMs in a proportion of INSTI-experienced individuals makes INSTI resistance testing mandatory after failure., (© 2022 British HIV Association.)

Published
2022
Full Text
View/download PDF

27. Optimal probability weights for estimating causal effects of time-varying treatments with marginal structural Cox models.

Author

Santacatterina M, García-Pareja C, Bellocco R, Sönnerborg A, Ekström AM, and Bottai M

Subjects
HIV Infections drug therapy, Humans, Longitudinal Studies, Observational Studies as Topic statistics & numerical data, Probability, Propensity Score, Prospective Studies, Registries, Sweden epidemiology, HIV Infections mortality, Proportional Hazards Models, Substance Abuse, Intravenous mortality
Abstract

Marginal structural Cox models have been used to estimate the causal effect of a time-varying treatment on a survival outcome in the presence of time-dependent confounders. These methods rely on the positivity assumption, which states that the propensity scores are bounded away from zero and one. Practical violations of this assumption are common in longitudinal studies, resulting in extreme weights that may yield erroneous inferences. Truncation, which consists of replacing outlying weights with less extreme ones, is the most common approach to control for extreme weights to date. While truncation reduces the variability in the weights and the consequent sampling variability of the estimator, it can also introduce bias. Instead of truncated weights, we propose using optimal probability weights, defined as those that have a specified variance and the smallest Euclidean distance from the original, untruncated weights. The set of optimal weights is obtained by solving a constrained quadratic optimization problem. The proposed weights are evaluated in a simulation study and applied to the assessment of the effect of treatment on time to death among people in Sweden who live with human immunodeficiency virus and inject drugs., (© 2018 John Wiley & Sons, Ltd.)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results